From: To what extent AstraZeneca ChAdOx1 nCoV-19 vaccine is safe and effective? Rapid systematic review
PR | 95% CI | P value | Chi square p value | I2 | Frequency | |
---|---|---|---|---|---|---|
Female | 0.683 | 0.569–0.797 | < 0.001 | < 0.001 | 99.983 | 427,613/635,109 |
Number of cases showing more than one adverse events | 0.717 | 0.339–1.094 | < 0.001 | < 0.001 | 99.99 | 123,969/353,302 |
Yougner people with at least one adverse event | 0.579 | 0.143–1.014 | 0.009 | < 0.001 | 99.998 | 36,191/171,241 |
Older people with at least one adverse event | 0.439 | 0.245–0.633 | < 0.001 | < 0.001 | 99.997 | 86,811/381,653 |
Systemic side effects | ||||||
Malaise | 0.717 | 0.479–0.955 | < 0.001 | < 0.001 | 99.019 | 1156/1537 |
Fatigue | 0.622 | 0.263–0.982 | < 0.001 | < 0.001 | 99.978 | 79,230/353,837 |
Headache | 0.569 | 0.288–0.850 | < 0.001 | < 0.001 | 99.951 | 84,436/353,837 |
Muscle pain | 0.516 | 0.035–0.998 | 0.036 | < 0.001 | 99.985 | 29,927/352,843 |
Chills | 0.483 | 0.189–0.778 | 0.001 | < 0.001 | 99.952 | 55,985/353,837 |
Joint pain | 0.357 | 0.142–0.572 | 0.001 | < 0.001 | 99.908 | 43,522/353,837 |
Fever | 0.346 | 0.109–0.582 | 0.004 | < 0.001 | 99.922 | 32149/353837 |
Nausea | 0.228 | 0.072–0.383 | 0.004 | < 0.001 | 99.608 | 20,341/348,248 |
Vomiting | 0.209 | 0.044–0.374 | 0.013 | < 0.001 | 99.774 | 1688/8014 |
Diarrhea | 0.154 | − 0.016–0.324 | 0.077 | < 0.001 | 99.879 | 9091/351,863 |
Bleeding | 0.149 | − 0.211–0.508 | 0.418 | 0.029 | 79.137 | 77/281,272 |
Local side effects | ||||||
Local pain | 0.645 | 0.203–1.087 | 0.004 | < 0.001 | 99.986 | 40,820/353,837 |
Itching | 0.415 | − 0.349–1.178 | 0.287 | < 0.001 | 100 | 8736/351,412 |
Swelling | 0.161 | 0.078–0.244 | < 0.001 | < 0.001 | 99.73 | 10,823/352,406 |
Redness | 0.14 | 0.080–0.199 | < 0.001 | < 0.001 | 99.61 | 8538/353,837 |
Skin rash | 0.031 | − 0.021–0.083 | 0.249 | < 0.001 | 99.65 | 1752/350,869 |
Death | 0.148 | − 0.211–0.508 | 0.418 | 0.028 | 79.161 | 18/281,272 |
Thrombosis events | ||||||
Percentage of thrombosis to total number of vaccinated Population | 0 | − 0.000–0.000 | 0.371 | 0.033 | 78.123 | 33/17,132,686 |
Number of cases showing more than one thrombosis events | 0.515 | 0.281–0.749 | < 0.001 | < 0.001 | 84.009 | 31/83 |
Deep venous thrombosis | 0.164 | − 0.005–0.333 | 0.057 | < 0.001 | 92.401 | 77/281,323 |
Thrombosis in other organs/areas | 0.323 | 0.108–0.538 | 0.003 | < 0.001 | 93.471 | 57/281344 |
Cerebral venous sinus thrombosis | 0.525 | 0.309–0.742 | < 0.001 | < 0.001 | 96.415 | 46/281,347 |
Pulmonary embolism | 0.191 | 0.028–0.353 | 0.021 | < 0.001 | 83.733 | 38/281,334 |
Splanchnic vein thrombosis | 0.103 | − 0.156–0.363 | 0.435 | 0.042 | 75.745 | 23/281,275 |
Death | 0.132 | 0.008–0.257 | 0.037 | < 0.001 | 79.289 | 29/281,334 |